Tarsus Pharmaceuticals (NASDAQ:TARS) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) released its earnings results on Tuesday. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08, Zacks reports. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $45.54 on Tuesday. The firm has a fifty day moving average price of $51.75 and a 200 day moving average price of $42.90. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a market cap of $1.74 billion, a P/E ratio of -11.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TARS shares. Barclays raised their price target on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Guggenheim reaffirmed a “buy” rating on shares of Tarsus Pharmaceuticals in a report on Monday. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.